Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Medtronic
AstraZeneca
Boehringer Ingelheim
Harvard Business School

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,855,703

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,855,703 protect, and when does it expire?

Patent 6,855,703 protects ENJUVIA and is included in one NDA.

This patent has eleven patent family members in seven countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,855,703
Title: Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
Abstract:A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated .DELTA..sup.8,9 -dehydroestrone, conjugated 17.alpha.-estradiol, conjugated 17.alpha.-dihydroequilin, conjugated 17.beta.-dihydroequilin, conjugated 17.beta.-estradiol, conjugated equilenin, conjugated 17.alpha.-dihydroequilenin, and conjugated 17.beta.-dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.
Inventor(s): Hill; Edward N. (Wilmington, NC), Leonard; Thomas W. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC), Schlipp; Katherin M. (Wilmington, NC), Shirazi; Dean G. (Wilmington, NC), Whittle; Robert R. (Wilmington, NC)
Assignee: Endeavor Pharmaceuticals (Wilmington, NC)
Application Number:09/524,132
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Drugs Protected by US Patent 6,855,703

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-003 May 10, 2004 DISCN No No   Start Trial   Start Trial Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-003 May 10, 2004 DISCN No No   Start Trial   Start Trial Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-005 Apr 27, 2007 DISCN No No   Start Trial   Start Trial Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,855,703

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2001245417   Start Trial
Australia 4541701   Start Trial
Canada 2402559   Start Trial
European Patent Office 1267852   Start Trial
Japan 2004500396   Start Trial
Japan 2011256181   Start Trial
South Korea 100804224   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Express Scripts
AstraZeneca
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.